FDA Aems Accepts E2b(R3) Updates Aligned With Ich E2d Standards

Pharmacovigilance teams and regulatory affairs leads submitting Individual Case Safety Reports to FDA's Adverse Event Monitoring System (AEMS) face updated data element requirements following the agency's alignment with the revised ICH E2D(R1) guideline, effective for postmarketing submissions now.

On March 6, 2026, FDA published its guidance titled E2D(R1) Postapproval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports (see 91 FR 10619). The guidance updates terminology, clarifies postapproval safety source definitions, and introduces new classification categories for solicited reports. Preceding that, on December 16, 2025, ICH released an Information Paper detailing how E2B(R3) specifications align with E2D(R1), specifically revising user guidance for data elements C.1.3 (Type of Report) and C.5.4 (Study Type Where Reaction(s)/Event(s) Were Observed).

The operational change with the most immediate submission impact is AEMS's acceptance of new values for data element C.5.4. These new values cover solicited reports originating from patient support programs (E2D(R1) section 4.5), market research programs (section 4.6), and organized data collection systems drawing source data from digital platforms (section 4.3.2). Manufacturers and outsourcing facilities that collect adverse event data through any of these channels must map their internal classification systems to the updated taxonomy before submitting ICSRs.

For premarketing submissions, FDA has consolidated implementation support across several documents, including the April 2024 Technical Specifications Document, FDA Regional Implementation Guide for E2B(R3), the April 2024 IND Safety Reports Guidance for Industry, and the December 2025 updates to sponsor and investigator safety reporting responsibilities. Postmarketing submitters should additionally reference the FDA E2B(R3) Forward Compatible Rules (April 2022) and the updated ICSR XML Instances package (July 2024). The ICH Information Paper on E2D(R1) alignment remains operative until FDA incorporates its content into the standing E2B(R3) Electronic Transmission Implementation Guide.

Regulatory affairs teams should audit current ICSR workflows against the revised C.5.4 value set and confirm that internal safety databases can generate compliant XML instances before the next scheduled postmarketing reporting cycle.

Source: FDA Drugs, What's New RSS Feed via fda.gov, September 30, 2026.